283 results on '"Fleischmann, Roy M."'
Search Results
2. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
3. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
4. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
5. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
6. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
7. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
8. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
9. Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
10. POS0849 Long-term safety and efficacy of Upadacitinib or adalimumab in patients with rheumatoid arthritis: 5-year data from the select-compare study
11. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
12. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
13. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis
14. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
15. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis
16. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
17. A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
18. RHEUMATOID ARTHRITIS: Developing new oral targeted therapies for RA can be challenging
19. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
20. Additional file 2 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
21. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study
22. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
23. Response to H Zeidlerʼs comments on the CONCERTO study
24. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
25. Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
26. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
27. Treatment of early rheumatoid arthritis
28. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
29. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
30. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
31. Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis.: 1320
32. A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate.: 1311
33. Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study.: 1316
34. Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis.: 1290
35. Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab.: 1286
36. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
37. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
38. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
39. EULAR PsA management recommendations 2019: can the recommendations be improved?
40. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
41. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
42. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, patients with rheumatoid arthritis receiving methotrexate
43. Golimumab, A Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-naive Patients With Active Rheumatoid Arthritis: Twenty-four-Week Results of A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Golimumab Before Methotrexate as First-line Therapy for Early-onset Rheumatoid Arthritis
44. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
45. Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective
46. Etanercept Added to Background Methotrexate Therapy in Patients With Rheumatoid Arthritis: Continued Observations
47. Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist (r-metHuIL-1ra), in Patients With Rheumatoid Arthritis: A Large, International, Multicenter, Placebo-Controlled Trial
48. Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Who Have Been Treated Unsuccessfully With Methotrexate: A Six-Month, Double-Blind, Randomized, Dose-Ranging Study
49. Etanercept Versus Methotrexate in Patients With Early Rheumatoid Arthritis: Two-Year Radiographic and Clinical Outcomes
50. Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain: Placebo-Controlled Trial and Long-term Evaluation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.